BioAmber Inc. is in the process of becoming a major player in the biobased succinic acid production market following its recent IPO. It is still at least six quarters away from achieving commercial-scale production, however, and the novelty of its pathway makes its commercialization prospects relatively uncertain. While management is optimistic that the company will achieve commercial-scale production by 2015, investors should be aware that the process is very uncertain and the risk of reductions to shareholder equity along the way is not low.
BioAmber Inc. (NYSE:BIOA) is a producer of biobased succinic acid. It is one of the newest additions to the ranks of publicly-traded companies that has opted to use biotechnology to produce biobased...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|